However, our observation that TIGIT inhibition may promote the anti-leukemic activity of NK-92 but not of CIML-NK cells raises the question of whether future composite biomarker analysis should not also include an in-depth functional assessment of the corresponding host immune cells, i.e., T and NK cells to enable a more comprehensive understanding of the intricate immune regulatory network of the PVR/Nectin family members, other immune CRs and their respective ligands on AML blasts. This evidence concerns the gene PVR and acute myeloid leukemia.